The Gut-Eye Axis and Mandagni: An Integrated Pathophysiological and Therapeutic Framework for Dry Eye Disease Management- A Review article

##plugins.themes.academic_pro.article.sidebar##

Published Feb 20, 2026
Download
Pdf Article download
Statistic
👁 Abstract Views: 0📥 Pdf Article download Downloads: 0
Vol. 10 No. 02 (2026): Agnibodh Conference Special Issue | AYURLINE: IJ-RIM

##plugins.themes.academic_pro.article.main##

Adarsh Ramkalap Sharma
a:1:{s:5:"en_US";s:55:"YMTAMC Kharghar, APM's Ayurved Mahavidyalaya,Sion, MUHS";}
Dr Ravidas More

Abstract

Abstract

Background: The Gut-Eye Axis (GEA) defines a crucial bidirectional link where intestinal integrity and microbial balance significantly modulate systemic inflammatory status, impacting ocular health. Dry Eye Disease (DED) is a widespread, chronic inflammatory disorder [1] frequently managed only symptomatically by conventional methods. The identification of systemic drivers is critical for achieving therapeutic breakthroughs.


Aim: To synthesize contemporary GEA research, focusing on DED pathogenesis via cytokine and metabolite pathways, with the classical Ayurvedic concepts of Agni (digestive fire), Ama (toxins), and Pitta vitiation. This integration aims to propose a unified, evidence-based diagnostic protocol and a three-phase integrated management strategy.


Methods: A narrative review was conducted, synthesizing clinical and preclinical studies on the GEA mechanism in ocular inflammation with classical Ayurvedic texts (Charaka Samhita[4] and Astanga Hrdayam[5]). The synthesis was established through the evaluation of functional homology between modern immunological markers and traditional Ayurvedic pathological processes.


Proposed Observation/Results: Gut Dysbiosis is demonstrated to be functionally homologous to Mandagni (impaired Agni), leading to the formation of systemically active endotoxins and inflammatory signaling molecules (Ama, such as LPS and pro-inflammatory cytokines). The subsequent DED-specific ocular surface damage and inflammation are primarily mediated by Pitta vitiation


Conclusion: The integrated GEA-Agni-Ama framework provides a sophisticated, personalized model for understanding DED etiology. A phased management protocol focusing sequentially on Agni restoration, gut barrier repair, and systemic Pitta expulsion promises a more holistic and effective approach to managing chronic DED.

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Sharma, A. R., & More, R. (2026). The Gut-Eye Axis and Mandagni: An Integrated Pathophysiological and Therapeutic Framework for Dry Eye Disease Management- A Review article. Ayurline: International Journal of Research in Indian Medicine, 10(02). Retrieved from https://ayurline.in/index.php/ayurline/article/view/1006

References

  1. 1. Navya R, Kolliyavar S. Unveiling the Gut-Eye Axis: The Role of the Microbiome in Ocular Health. Int J Multidiscip Res. 2025;7(3):45318.
  2. 2. Dohlman TH, Vandekerckhove LP, Drolsum L, et al. Gut microbiome and its role in ocular health and disease. Acta Ophthalmol. 2024;102(2):120-130.
  3. 3. Lee H, Lee D, Kim Y. Consumption of Limosilactobacillus fermentum Inhibits Corneal Damage and Inflammation in Dry Eye Disease Mice Model through Regulating the Gut Microbiome. J Transl Med. 2023;21(1):198.
  4. 4. Sharma RK, Dash B. Charaka Samhita. Vol 1-7. Chowkhamba Sanskrit Series Office; 2018.
  5. 5. Murthy KRS. Astanga Hrdayam of Vagbhata. 10th ed. Krishnadas Academy; 2016.
  6. 6. Ray S, et al. Functional Weak Agni (Mandagni) and its pivotal importance in the pathogenesis of Grahani Roga. Ayu. 2011;32(4):460-466.
  7. 7. Amer R, Alon T. The gut-eye axis in uveitis: clinical and experimental evidence. Int Ophthalmol. 2021;41(10):3455-3466.
  8. 8. Li Z, Wang J, Shi P, et al. Th17/Treg imbalance and related cytokines in non-Sjögren's dry eye syndrome pathogenesis. Mol Immunol. 2020;124:20-27.
  9. 9. Lee JJ, et al. Probiotics suppress autoimmune dry eye via downregulation of antigen-presenting processes. Invest Ophthalmol Vis Sci. 2020;61(11):23.
  10. 10. Moon K, et al. The gut-eye axis: lessons learned from murine models. Ophthalmol Ther. 2020;9:499–513.
  11. 11. Chen X. Short-chain fatty acids inhibit LPS-induced intraocular inflammation. Sci Rep. 2021;11(1):19894.
  12. 12. Gupta SK, et al. Immunomodulatory and anti-inflammatory activities of Triphala. J Ethnopharmacol. 2016;186:163-172.
  13. 13. Lu Q, Li X. Butyrate suppresses pro-inflammatory gene expression in corneal explants in vitro and ameliorates ocular surface disease in a dry eye disease mouse model. J Clin Invest. 2022;132(6):e150923.
  14. 14. Liu S, et al. Emblica officinalis protects RPE cells from mitochondria-induced cellular damage in Age-related Macular Degeneration. Aging (Albany NY). 2021;13(15):19616-19632.
  15. 15. Zhou X, Zhang J, Li Q, et al. Gut dysbiosis–ocular surface–lacrimal gland axis: an update. Contact Lens Assoc Ophthalmol J. 2022;48(6):309-315.
  16. 16. Zuo T, et al. Gut microbiome restoration by Virechana. BMC Complement Altern Med. 2018;18(1):210.
  17. 17. Sharma M, Das A. Review of Triphala and Trikatu on their anti-inflammatory potential. Int J Pharm Sci Drug Res. 2022;14(2):100-107.